The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Linezolid for Treatment of Chronic Extensively Drug-Resistant Tuberculosis
Open accessAbstract
BACKGROUND: Linezolid has antimycobacterial activity in vitro and is increasingly used for patients with highly drug-resistant tuberculosis. METHODS: We enrolled 41 patients who had sputum-culture-positive extensively drug-resistant (XDR) tuberculosis and who had not had a response to any available chemotherapeutic option during the previous 6 months. Patients were randomly assigned to linezolid therapy that started immediately or after 2 months, at a dose of 600 mg per day, without a change in their background regimen. The primary end point was the time to sputum-culture conversion on solid medium, with data censored 4 months after study entry. After confirmed sputum-smear conversion or 4 months (whichever came first), patients underwent a second randomization to continued linezolid therapy at a dose of 600 mg per day or 300 mg per day for at least an additional 18 months, with careful toxicity monitoring. RESULTS: By 4 months, 15 of the 19 patients (79%) in the immediate-start group and 7 of the 20 (35%) in the delayed-start group had culture conversion (P=0.001). Most patients (34 of 39 [87%]) had a negative sputum culture within 6 months after linezolid had been added to their drug regimen. Of the 38 patients with exposure to linezolid, 31 (82%) had clinically significant adverse events that were possibly or probably related to linezolid, including 3 patients who discontinued therapy. Patients who received 300 mg per day after the second randomization had fewer adverse events than those who continued taking 600 mg per day. Thirteen patients completed therapy and have not had a relapse. Four cases of acquired resistance to linezolid have been observed. CONCLUSIONS: Linezolid is effective at achieving culture conversion among patients with treatment-refractory XDR pulmonary tuberculosis, but patients must be monitored carefully for adverse events. (Funded by the National Institute of Allergy and Infectious Diseases and the Ministry of Health and Welfare, South Korea; ClinicalTrials.gov number, NCT00727844.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Asymptotically Efficient Rank Invariant Test Procedures
Peto, R., & Peto, J. (1972) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344317 · Cited by 3,393
Streptomycin Treatment of Pulmonary Tuberculosis: A Medical Research Council Investigation
(1948) · BMJ · doi:10.1136/bmj.2.4582.769 · Cited by 986
The Diarylquinoline TMC207 for Multidrug-Resistant Tuberculosis
Diacon, A. H., Pym, A., Grobusch, M., Patientia, R., Rustomjee, R., Page-Shipp, L., Pistorius, C., Krause, R., Bogoshi, M., Churchyard, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808427 · Cited by 835
STREPTOMYCIN treatment of pulmonary tuberculosis.
D’Esopo, N. D., & Allison, S. T. (1947) · PubMed · Cited by 606
Repeated assessment of results in clinical trials of cancer treatment
Haybittle, J. L. (1971) · The British Journal of Radiology · doi:10.1259/0007-1285-44-526-793 · Cited by 517
In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents
Zurenko, G. E., Yagi, B. H., Schaadt, R. D., Allison, J. W., Kilburn, J. O., Glickman, S. E., Hutchinson, D. K., Barbachyn, M. R., & Brickner, S. J. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.4.839 · Cited by 461
Rustomjee, R., Lienhardt, C., Kanyok, T. P., Davies, G., Levin, J., Mthiyane, T., Reddy, C., Sturm, A. W., Sirgel, F. A., Allen, J., et al. (2008) · PubMed · Cited by 326
Crystal Structure of the Oxazolidinone Antibiotic Linezolid Bound to the 50S Ribosomal Subunit
Ippolito, J. A., Kanyo, Z. F., Wang, D., Franceschi, F. J., Moore, P. B., Steitz, T. A., & Duffy, E. M. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm800379d · Cited by 303
Dorman, S. E., Johnson, J. L., Goldberg, S., Muzanye, G., Padayatchi, N., Bozeman, L., Heilig, C. M., Bernardo, J., Choudhri, S., Grosset, J. H., et al. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200901-0078oc · Cited by 264
Activities of Several Novel Oxazolidinones against Mycobacterium tuberculosis in a Murine Model
Cynamon, M. H., Klemens, S. P., Sharpe, C. A., & Chase, S. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.5.1189 · Cited by 243
Linezolid for the treatment of multidrug-resistant tuberculosis
Fortún, J., Martín-Dávila, P., Navas, E., Pérez-Elías, M. J., Cobo, J., Tato, M., De la Pedrosa, E. G.-G., Gómez-Mampaso, E., & Moreno, S. (2005) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dki148 · Cited by 225
Linezolid: a review of safety and tolerability
Vinh, D. C., & Rubinstein, E. (2009) · Journal of Infection · doi:10.1016/s0163-4453(09)60009-8 · Cited by 213
Linezolid, the first oxazolidinone antibacterial agent
Leach, K. L., Brickner, S. J., Noe, M. C., & Miller, P. F. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.05962.x · Cited by 195
Early and Extended Early Bactericidal Activity of Linezolid in Pulmonary Tuberculosis
Dietze, R., Hadad, D. J., McGee, B., Molino, L. P. D., Maciel, E. L. N., Peloquin, C. A., Johnson, D. F., Debanne, S. M., Eisenach, K., Boom, W. H., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200806-892oc · Cited by 165
Boselli, E., Breilh, D., Rimmelé, T., Djabarouti, S., Toutain, J., Chassard, D., Saux, M.-C., & Allaouchiche, B. (2005) · Critical Care Medicine · doi:10.1097/01.ccm.0000168206.59873.80 · Cited by 164
Park, I.-N. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl298 · Cited by 161
Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB)—a report of ten cases
von der Lippe, B., Sandven, P., & Brubakk, O. (2005) · Journal of Infection · doi:10.1016/j.jinf.2005.04.007 · Cited by 142
Oxazolidinones Inhibit Cellular Proliferation via Inhibition of Mitochondrial Protein Synthesis
Nagiec, E. E., Wu, L., Swaney, S. M., Chosay, J. G., Ross, D., Brieland, J. K., & Leach, K. L. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.9.3896-3902.2005 · Cited by 120
First Linezolid-Resistant Clinical Isolates of Mycobacterium tuberculosis
Richter, E., Rüsch–Gerdes, S., & Hillemann, D. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01113-06 · Cited by 117
Beckert, P., Hillemann, D., Kohl, T. A., Kalinowski, J., Richter, E., Niemann, S., & Feuerriegel, S. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06227-11 · Cited by 116
Sander, P., Belova, L., Kidan, Y. G., Pfister, P., Mankin, A. S., & Böttger, E. C. (2002) · Molecular Microbiology · doi:10.1046/j.1365-2958.2002.03242.x · Cited by 102
Beekmann, S. E., Gilbert, D. N., & Polgreen, P. M. (2008) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2008.08.009 · Cited by 93
Pharmacological Issues of Linezolid: An Updated Critical Review
Paolo, A. D., Malacarne, P., Guidotti, E., Danesi, R., & Tacca, M. D. (2010) · Clinical Pharmacokinetics · doi:10.2165/11319960-000000000-00000 · Cited by 85
Rodríguez, J. C., Cebrián, L., López, M., Ruiz, M., Jiménez, I., & Royo, G. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh119 · Cited by 80
Ashtekar, D. R., Costa-Periera, R., Shrinivasan, T., Iyyer, R., Vishvanathan, N., & RITTEL, W. (1991) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/0732-8893(91)90002-w · Cited by 74
Population Pharmacokinetics of Linezolid in Adults with Pulmonary Tuberculosis
McGee, B., Dietze, R., Hadad, D. J., et al. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01378-08 · Cited by 63
Early clinical development of anti-tuberculosis drugs: Science, statistics and sterilizing activity
Davies, G. (2010) · Tuberculosis · doi:10.1016/j.tube.2010.03.007 · Cited by 51
Cited by
Pai, M., Behr, M. A., Dowdy, D., Dheda, K., Divangahi, M., Boehme, C. C., Ginsberg, A., Swaminathan, S., Spigelman, M., Getahun, H., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.76 · Cited by 1,270
Treatment of Highly Drug-Resistant Pulmonary Tuberculosis
Conradie, F., Diacon, A. H., Ngubane, N., Howell, P., Everitt, D., Crook, A. M., Mendel, C. M., Egizi, E., Moreira, J., Timm, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1901814 · Cited by 1,044
Advances in the development of new tuberculosis drugs and treatment regimens
Zumla, A., Nahid, P., & Cole, S. T. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4001 · Cited by 893
Furin, J., Cox, H., & Pai, M. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30308-3 · Cited by 873
Zumla, A., Raviglione, M., Hafner, R., & Fordham von Reyn, C. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1200894 · Cited by 698
Metadata
- Authors
- Lee, M., Lee, J., Carroll, M. W., Choi, H., Min, S., Song, T., Via, L. E., Goldfeder, L. C., Kang, E., Jin, B., Park, H., Kwak, H., Kim, H., Jeon, H.-S., Jeong, I., Joh, J. S., Chen, R. Y., Olivier, K. N., Shaw, P. A., Follmann, D., Song, S. D., Lee, J.-K., Lee, D., Kim, C. T., Dartois, V., Park, S.-K., Cho, S.-N., & Barry, C. E.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-10-18
- Volume
- 367
- Issue
- 16
- Pages
- 1508-1518
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1964291085
- Cited by
- 560
- References
- 27
- FWCI
- 34.81
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.